DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) cells represent a significant advancement in cancer immunotherapy, particularly for hematological malignancies.
• CAR cell therapy is being explored for solid tumors, necessitating a deeper understanding of its pharmacokinetic and metabolic profiles.

Purpose of the Study:

• To provide a comprehensive review of the current status and challenges in drug metabolism and pharmacokinetics (DMPK) for CAR cell therapy.
• To highlight the role of quantitative modeling and simulation (M&S) in addressing these DMPK challenges.
• To outline future perspectives and areas for improvement in CAR cell therapy translation.

Main Methods:

• Review of current literature on CAR cell therapy and DMPK.
• Emphasis on quantitative modeling and simulation (M&S) approaches.
• Analysis of recent advances in quantitative model analysis, including clinical data characterization and mechanism-based modeling.

Main Results:

• CAR cell therapy has shown revolutionary success in hematological cancers and is under investigation for solid tumors.
• Quantitative modeling and simulation are essential tools for characterizing CAR cell therapy's DMPK.
• Advances include connecting in vitro and in vivo data through mechanism-based modeling.

Conclusions:

• Addressing DMPK challenges through a robust framework is pivotal for successful CAR cell therapy translation.
• Improvements in formulation quality, animal models, in vitro models, and bioanalytical methods are needed.
• Enhanced DMPK understanding will facilitate efficient CAR cell therapies, improving patient lives.